Skip to main content Accessibility help
×
Home

Probing the Function of 5-HT1B/1D Receptors in Psychiatric Patients

  • Richard Whale and Philip J. Cowen

Abstract

Pharmacological challenge tests provide a method of assessing the functional responsiveness of serotonin (5-HT) receptor subtypes in the human brain. A number of selective agonist ligands for the 5-HT1B/1D receptor are available for human use; however, these compounds do not distinguish between 5-HT1B and 5-HT1D receptors, which is somewhat of a disadvantage. Acute administration of sumatriptan, rizatriptan, and zolmitriptan all increase plasma growth hormone in healthy subjects, possibly via activation of postsynaptic 5-HT1D receptors. This response is blunted in major depression. Sumatriptan lowers plasma prolactin, perhaps via activation of presynaptic 5-HT1B receptors. This response is not altered during repeated treatment with selective serotonin reuptake inhibitors (SSRIs), suggesting that 5-HT1B receptors retain the ability to restrain 5-HT outflow during short-term SSRI treatment.

Copyright

References

Hide All
1.Cowen, PJ. Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation. Clin Neuropharmacol. 1993;16(suppl):S6S18.
2.Wilkinson, LO, Middlemiss, DN. The autoregulation of 5-HT release from nerve terminals in vitro. In: Bradley, PB, Handley, SL, Cooper, SJ, Key, BJ, Barnes, NM, Coote, JH, eds. Serotonin, CNS Receptors and Brain Function. Oxford, England: Pergamon; 1992:111.
3.Kennett, GA, Dourish, CT, Curzon, G. 5-HT1B agonists induce anorexia at a postsynaptic site. Eur J Pharmacol. 1987;141:429435.
4.Lee, MD, Simansky, KJ. CP-94,253: selective serotonin IB (5-HT1B) agonist that promotes satiety. Psychopharmacobgy. 1997;131:264270.
5.Hatcher, JP, Slade, PD, Roberts, C, Hagan, JJ. 5-HT1D receptors mediate SKF-99101H induced hypothermia in the guinea-pig. J Psychopharmacol (Oxf). 1995;9:234241.
6.Hagan, JJ, Slade, PD, Caster, L, Jeffrey, P, Hatcher, JP, Middlemiss, DN. Stimulation of 5-HT1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol. 1997;331:169174.
7.Dallas, FA, Dixon, CN, McCulloch, RJ, Saynor, DA. The kinetics of 14 C-GR43175 in rat and dog. Cephalalgia. 1989;9(suppl):5356.
8.Goadsby, PJ, Edvinsson, L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin 5-HT1D receptor agonist 311C90. Headache. 1994;34:394399.
9.Humphrey, PP, Feniuk, W, Marriott, AS, Tanner, RJ, Jackson, MR, Tucker, ML. Preclinical studies on the antimigraine drug, sumatriptan. Eur Neurol. 1991;31:282290.
10.Sharpley, AL, Cowen, PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry. 1995;37:8598.
11.Park, SB, Coull, JT, McShane, RH, et al.Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology. 1994;33:575588.
12.Walsh, AES, Smith, KA, Oldman, AD, Williams, C, Goodall, EM, Cowen, PJ. M-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (Bed). 1994;116:120122.
13.Herdman, JRE, Delva, NJ, Hockney, RA, Campling, GM, Cowen, PJ. Neuroendocrine effects of sumatriptan. Psychopharmacology. 1994;113:561564.
14.Boeles, S, Williams, C, Campling, GM, Goodall, EM, Cowen, PJ. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology. 1997;129:179182.
15.Sciberras, DG, Polvino, WJ, Gertz, BJ, et al.Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. Br J Pharmacol. 1997;43:4954.
16.Facchinetti, F, Nappi, RE, Sanees, G, Fioroni, L, Nappi, G, Genazzani, AR. The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1–like receptors. Clin Endocrinol (Oxf). 1994;40:211214.
17.Franceschini, R, Cataldi, A, Garibaldi, A, et al.The effects of sumatriptan on pituitary secretion in man. Neuropharmacology. 1994;33:235239.
18.Markianos, M, Lykouras, L, Hatzimanolis, J, Bistolaki, E. Effects of the serotonin receptor agonist sumatriptan on hormonal plasma levels in healthy and depressed subjects: a placebo controlled study. Neuroendocrinology. 1994;16:6571. Letter.
19.Whale, R, Cowen, PJ. Sumatriptan lowers plasma prolactin in healthy female volunteers. Psychopharmacology. 1998;137:203204.
20.Eckland, DJ, Entwisle, SJ, Fowler, PA, et al.The effects of sumatriptan, a 5-HT1-like agonist on pituitary adrenal function in healthy volunteers. Br J Clin Pharmacol. 1992;33:538.
21.Peroutka, SJ, McCarthy, BG. Sumatriptan (GR43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989;163:133136.
22.Martin, GR, Robertson, AD, MacLennan, SJ, et al.Receptor specificity and trigémino-vascular inhibitory action of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121:157164.
23.Peroutka, SJ. Pharmacological differentiation of human 5-HT1B and 5-HT1D receptors. Biol Signals. 1994;3:217222.
24.Van de Kar, LD. Neuroendocrine pharmacology of serotonergic (5-HT) neurones. Annu Rev Pharmacol Toxicol. 1991;31:289320.
25.Johnson, KW, Schaus, JM, Durkin, MM, et al.5-HT1E receptor agonists inhibit neurogenic durai inflammation in guinea pigs. Neuroreport. 1997;8:22372240.
26.Smith, KA, Cowen, PJ. Depression: neurobiological, psy-chopathological and therapeutic advances. In: Honig, A, van Praag, HM, eds. Serotonin and Depression. Chichester, England: John Wiley & Sons; 1997:129146.
27.Lesch, KP. 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry. 1992;15:723733.
28.Meltzer, HY, Maes, M. Effects of ipsapirone on plasma Cortisol and body temperature in major depression. Biol Psychiatry. 1995;38:450457.
29.Yatham, LN, Raymond, WL, Athanasios, PZ. Growth hormone response to sumatriptan (5-HT1D agonist) challenge in seasonal affective disorder: effects of light therapy. Biol Psychiatry. 1997;42:2429.
30.Yatham, LN, Athanasios, PZ, Lam, RW, Tam, E, Shiah, I-S. Sumatriptan-induced growth hormone release in patients with major depression, mania and normal controls. Neuropsychopharmacology. 1997;17:258263.
31.Cleare, AJ, Murray, RM, Sherwood, RA, O'Keane, V. Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan. Psychol Med. 1998;28:295300.
32.LaPorta, LD. Recurrent depression after sumatriptan administration for treatment of migraine. J Clin Psychopharmacol. 1995;15:8182.
33.Smith, KA, Fairburn, CG, Cowen, PJ. Relapse of depression after rapid depletion of tryptophan. Lancet. 1997;349:915919.
34.Zohar, J, Mueller, EA, Insel, TR, Zohar-Kadouch, RC, Murphy, DL. Serotonin responsivity in obsessive-compulsive disorder. Arch Gen Psychiatry. 1987;44:946951.
35.Zohar, J. Is 5-HT1D involved in obsessive compulsive disorder? Journal of European College of Neuropsychopharmacology. 1996;6(suppl 4):S454. Abstract.
36.Ho Pian, KL, Westenberg, HGM, van Megen, HJGM, den Boer, JA. Sumatriptan (5-HTin receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology. 1998. In press.
37.Moret, C, Briley, M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol. 1990;180:351356.
38.Blier, P, Bouchard, C. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br J Pharmacol. 1994;113:485495.
39.Wing, Y-K, Clifford, EM, Sheehan, BD, Campling, GM, Hockney, RA, Cowen, PJ. Paroxetine treatment and the prolactin response to sumatriptan. Psychopharmacology. 1996;124:377379.
40.Gundlah, C, Hjorth, S, Auerbach, SB. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalo-pram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology. 1997;36:475482.
41.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Ed. Revised. Washington, DC: American Psychiatric Press; 1980.

Related content

Powered by UNSILO

Probing the Function of 5-HT1B/1D Receptors in Psychiatric Patients

  • Richard Whale and Philip J. Cowen

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.